News | Health & Safety
22 Jul 2017 12:52
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • Sport
  • Weather
  • Olympic Games
  • Ski Report
  • Finance
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Health & Safety

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.


    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Health & Safety News
     22 Jul: Birth control: Natural methods of contraception on the rise in Australia
     21 Jul: Synthetic cannabis: size and scope
     21 Jul: Synthetic drug deaths 'foreseeable': Dunne
     21 Jul: Doctor jailed for child porn worked in NZ
     20 Jul: Big health gains to bowel screening: study
     20 Jul: Kiwi's death triggers Japanese campaign
     19 Jul: NZD gains as US healthcare reform stumbles
     Top Stories

    RUGBY RUGBY
    Winning Hurricanes desperate to improve More...


    BUSINESS BUSINESS
    NRL announce Knights sale to Wests Group More...



     Today's News

    Environment:
    Drunk, hypothermic group rescued in floods 12:37

    Auckland:
    Slip blocks SH1 north of Auckland 12:37

    International:
    Five-year-old's lemonade stall on London street attracts $246 fine 12:27

    Politics:
    Ardern would give up deputy PM spot 12:27

    Environment:
    Chch declares state of emergency amid rain 12:17

    Business:
    NRL announce Knights sale to Wests Group 11:57

    Law and Order:
    Justine Damond: Minneapolis Police Chief resigns after officer's fatal shooting of Australian woman 11:17

    Golf:
    Final-hole birdie saves Ko from early exit 11:07

    Athletics:
    Willis times qualifying run to perfection 10:27

    Environment:
    Winning Hurricanes desperate to improve 10:07


     News Search






    Power Search


    © 2017 New Zealand City Ltd